Applied Therapeutics, Omeros, and Others Experience Significant Price Changes After Market Close
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Source: NASDAQ.COM
Milestone Scientific Inc. Earnings: Milestone Scientific's shares rose 36.10% after reporting a third-quarter net loss of $1.2 million, with revenue slightly down to $2.4 million due to weaker domestic dental sales but stronger international demand.
Applied Therapeutics Inc. Update: Applied Therapeutics saw a 14.78% increase in shares after narrowing its Q3 net loss to $19 million and announcing a meeting with the FDA to discuss the regulatory path for govorestat in Classic Galactosemia.
Omeros Corp. Financial Results: Omeros Corp. shares gained 20.54% following a Q3 net loss of $30.9 million, with an update on its Biologics License Application for narsoplimab and an extended FDA action date to December 2025.
The Oncology Institute Inc. Performance: The Oncology Institute's shares rose 19.48% after reporting a 36.7% increase in Q3 revenue to $136.6 million, while also raising its full-year revenue guidance to between $495 million and $505 million.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on TOI
Wall Street analysts forecast TOI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TOI is 6.67 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.000
Low
5.00
Averages
6.67
High
8.00
Current: 3.000
Low
5.00
Averages
6.67
High
8.00
About TOI
The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
M33 Growth Partners with US Neurology Associates to Transform Neurology Care
- Strategic Partnership: M33 Growth partners with US Neurology Associates to enhance the quality of neurology care by integrating resources and infrastructure to meet the growing patient demand.
- Leadership Team: Nitin Jain as CEO and Brad Hively as Chairman bring extensive management experience in healthcare, which will drive the company's growth.
- Innovative Care Platform: USNA will deliver comprehensive care including in-office infusions, diagnostics, and clinical trials, aiming to improve patient experience and reduce care costs through a one-stop service.
- Value-Oriented Approach: USNA is committed to collaborating with payers to promote value-based care models, aiming to provide efficient and cost-effective neurology solutions through integrated community clinics.
Continue Reading
The Oncology Institute Appoints New CIO and CPO to Enhance Leadership in Value-Based Cancer Care
- Leadership Changes: The Oncology Institute has appointed Rakesh Panda as Chief Information Officer, leveraging over 25 years of IT and digital transformation experience to advance the company's technology strategy, particularly in AI and data privacy, aimed at enhancing value-based cancer care.
- HR Strengthening: Nolan Mariano has been appointed Chief People Officer, overseeing HR operations and talent acquisition, and with 18 years of industry experience, he will enhance company culture and employee development to support the rapid growth of The Oncology Institute.
- Technology-Driven Care Platform: The new CIO will focus on the technology-enabled care delivery platform, driving innovations to improve patient experience and care quality, thereby strengthening the company's competitive position in the cancer care market.
- Sustained Growth Strategy: CEO Daniel Virnich emphasized the promotion of internal leaders, indicating the company's commitment to providing world-class community-based cancer care while continuing to experience rapid growth, further solidifying its leadership position in the industry.
Continue Reading